STERLING, Va., Dec. 14 /PRNewswire/ -- NanoMarkets, a leading industry consultancy based here, today announced the release of two white papers that address the role of nanotechnology in drug discovery and drug delivery. The papers are available for immediate download from the firm's web site, http://www.nanomarkets.net. Background: As the pharmaceutical industry matures, meeting Wall Street's aggressive growth expectations becomes increasingly difficult. Many companies will continue to grow via merger and acquisition activity and through internal development of high-value compounds. Nonetheless, over the next decade, several blockbuster drugs will go off patent, resulting in an estimated loss of $30-$40 billion in annual product revenues as generic drugs enter the market. This change is accelerating the industry's constant need to "build the pipeline" of new compounds, and to rapidly enter new markets. Naturally, these trends are creating new challenges and opportunities in drug discovery. It is also a significant driver of change in Drug Delivery Systems (DDS), which are increasingly being used to alleviate some of the industry's concerns by extending product and patent lifecycles, creating New Chemical Entities (NCE's) via reformulation of existing and/or orphaned compounds, and subsequent creation of value for shareholders and consumers. When you add in the massive amount of nanotechnology and pharmaceutical R&D funding now available worldwide, the drug delivery industry is evolving rapidly and is nearly unrecognizable from its humble beginnings in the 1960's. This $40- billion market has seen double-digit growth for the past two decades, and the industry's success has spawned intense competition. NanoMarkets believes that important opportunities exist at the intersection of nanotechnology and traditional pharmaceutical R&D, though much uncertainty remains on how this will affect the industry. About the Papers: The first paper titled, "Factors Pushing the Growth of Nano-Enabled Drug Discovery," examines how nanotechnology can enhance the drug discovery process and discusses how various economic, technical, financial and societal trends are pointing to real opportunities. Although at an embryonic stage of development, nano-enabled drugs are already bringing clinical benefits to thousands of patients. The second paper titled, "The Nano-Enabled Drug Delivery Systems Market," discusses the contributions that nanotechnology is making to the pharmaceutical industry in the areas of solubility enhancements, reduced development costs, greater targeting availability and consumer- friendly products. The paper goes on to examine market competition, challenges and trends pointing toward a greater need for nanotech based solutions. About NanoMarkets' Research Program: NanoMarkets is currently conducting an extensive examination of the opportunities for the application of nanotechnology in the pharmaceutical sector. The first deliverables will be available early in the first quarter of 2005 and will address the major drivers, restraints and challenges for current and emerging applications of nanotechnology in drug discovery and drug-delivery markets. NanoMarkets is making the reports available at a discounted rate through the end of 2004. For additional information about these reports, you may contact Robert Nolan at firstname.lastname@example.org or (571) 434-7520 or visit http://www.nanomarkets.net to learn more. About NanoMarkets: NanoMarkets analyzes the impact of nanotechnology on both established and emerging markets with a focus on the realms of communications, IT, semiconductors, bio-medical and energy. The firm provides market research reports, customized industry analyses and general market commentary for companies looking to capitalize on nanotechnology-based opportunities.